Search Result

Results for "

thrombin time

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Thrombin (11) Amyloid-β (2) Bacterial (2) Biochemical Assay Reagents (2) Cathepsin (1) Dihydroorotate Dehydrogenase (2) Drug Isomer (1) Drug Metabolite (1) Endogenous Metabolite (1) ERK (1) Factor Xa (6) Ferroptosis (2) Glutathione Peroxidase (2) Heme Oxygenase (HO) (2) Insecticide (2) Keap1-Nrf2 (2) NF-κB (2) PAI-1 (2) Proton Pump (2) Reference Standards (1) Toll-like Receptor (TLR) (2) TRP Channel (2)
By Research Areas:	Cancer (2) Cardiovascular Disease (18) Infection (2) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (2)

By Targets:

Thrombin (11)

Amyloid-β (2)

Bacterial (2)

Biochemical Assay Reagents (2)

Cathepsin (1)

Dihydroorotate Dehydrogenase (2)

Drug Isomer (1)

Drug Metabolite (1)

Endogenous Metabolite (1)

ERK (1)

Factor Xa (6)

Ferroptosis (2)

Glutathione Peroxidase (2)

Heme Oxygenase (HO) (2)

Insecticide (2)

Keap1-Nrf2 (2)

NF-κB (2)

PAI-1 (2)

Proton Pump (2)

Reference Standards (1)

Toll-like Receptor (TLR) (2)

TRP Channel (2)

By Research Areas:

Cancer (2)

Cardiovascular Disease (18)

Infection (2)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Thrombin Protease Activated Receptor (PAR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0074

GPRP 3 Publications Verification Gly-Pro-Arg-Pro; Pefa 6003	Thrombin	Cardiovascular Disease
GPRP (Gly-Pro-Arg-Pro; Pefa 6003) is a fibrin polymerization inhibitor that inhibits the interaction between fibrinogen and the platelet membrane glycoprotein Ⅱb/IIIa complex (glycoprotein IIb/IIIa receptor) . GPRP increases the level of free thrombin in activated platelet-rich plasma by reducing the adsorption of *thrombin* onto fibrin. GPRP inhibits platelet aggregation and prolongs the thrombin-initiated clotting time in plasma. GPRP is applicable for research related to thrombosis and thrombotic diseases .

HY-N3097

Pellitorine	TRP Channel Amyloid-β Toll-like Receptor (TLR) Keap1-Nrf2 Heme Oxygenase (HO) Dihydroorotate Dehydrogenase Ferroptosis PAI-1 NF-κB ERK Proton Pump Glutathione Peroxidase Thrombin Insecticide Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria .

HY-P99794

Osocimab BAY 1213790	Factor Xa	Cardiovascular Disease
Osocimab (BAY 1213790), an anti-FXIa antibody (K_i=2.4 nM; EC₅₀=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .

HY-N2138

Buddlejasaponin IVb	Others	Inflammation/Immunology
Buddlejasaponin IVb (Compound 2), a triterpene saponin isolated from Clinopodium chinense (Benth.) O. Kuntze, Compound 2 has hemostasis efficacy, shortens thrombin time (TT) by 20.6 % .

HY-N3701

Decursidate	Others	Others
Decursidate is an active compound. Decursidate can prolong thrombin time .

HY-122813

Dabigatran acyl-β-D-glucuronide	Drug Metabolite Thrombin	Cardiovascular Disease
Dabigatran acyl-β-D-glucuronide is an active metabolite of the thrombin inhibitor Dabigatran (HY-10163). Dabigatran acyl-β-D-glucuronide increases activated partial thromboplastin time (aPTT) in isolated human platelet-poor plasma.

HY-166257

Lyso-sulfatide (bovine) Psychosine 3′-O-sulfate; Psychosine 3′-sulfate	Biochemical Assay Reagents Factor Xa	Metabolic Disease
Lyso-sulfatide (bovine) is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions .

HY-172905

BCX-3607	Others	Cardiovascular Disease
BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC₅₀: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases .

HY-106404

RPR 130737	Factor Xa	Cardiovascular Disease
RPR 130737 is a selective, potent and competitive inhibitor for factor Xa with a K_i of 2.4 nM. RPR 130737 shows selectivity of more than 1000-fold over thrombin, activated protein C, plasmin, tissue-plasminogen activator and trypsin. RPR 130737 can prolong plasma activated partial thromboplastin time and prothrombin time. RPR 130737 shows no effect on platelet aggregation. RPR 130737 can be used for the research of cardiovascular disease, such as thrombosis .

HY-170485

Thrombin inhibitor 13	Thrombin	Cardiovascular Disease
Thrombin inhibitor 13 (Compound 13a) is a covalent and reversible inhibitor for *thrombin* (FIIa) with an IC₅₀ of 0.7 nM. Thrombin inhibitor 13 prolongs the activated partial thromboplastin time (aPTT) and prothrombin time (PT), exhibits antithrombotic and anticoagulant activities .

HY-P4302

Z-FK-ck Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone	Cathepsin	Cardiovascular Disease
Z-FK-ck (Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone) is a potent and selective gingipain-K-specific inhibitor. Z-FK-ck prolongs plasma thrombin time (TT) in a dose- and time-dependent manner .

HY-19674

SSR182289 SSR182289A free base	Thrombin	Cardiovascular Disease
SSR182289 (SSR182289A free base) is a selective and potent orally active *thrombin* inhibitor. SSR182289 competitively and selectivity inhibits human thrombin (K_i=0.031 μM). SSR182289 demonstrates anticoagulant activity in vitro (thrombin time EC₁₀₀=96 nM) and inhibits tissue factor-induced thrombin generation (IC₅₀=0.15 μM) in human plasma. SSR182289 inhibits thrombin-induced aggregation of human platelets (IC₅₀=32 nM), but has no effect on aggregation induced by other platelet agonists .

HY-10281

YM-60828 methanesulfonate	Factor Xa	Cardiovascular Disease
YM-60828 is an FXa inhibitor with antithrombotic properties. In the rat arteriovenous shunt model, YM-60828 does not prolong coagulation time but reduces the levels of thrombin-antithrombin III complex (TAT) in a dose-dependent manner. YM-60828 exhibits only anti-FXa activity and does not show anti-thrombin activity, indicating that its antithrombotic effect is independent of thrombin. Therefore, the antithrombotic effect of YM-60828 can be monitored by TAT .

HY-19222

CVS-1123	Thrombin	Cardiovascular Disease
CVS-1123 is an orally active direct thrombin inhibitor. CVS-1123 inhibits in vitro platelet aggregation of γ-thrombin and prolongs activated partial thromboplastin time. CVS-1123 alters the thrombotic response to deep vessel wall damage in arterial and venous circulation. CVS-1123 can be used in antithrombotic studies

HY-N13960

Bacithrocin D Thiolstatin D	Thrombin Factor Xa	Cardiovascular Disease
Bacithrocin D (Thiolstatin D) inhibits multiple proteases and can prolong the clotting time. Bacithrocin D has IC₅₀ values of 124, 9, 0.85, and 0.01 μM for thrombin, factor Xa, trypsin, and papain, respectively .

HY-N3097R

Pellitorine (Standard)	Reference Standards TRP Channel Amyloid-β Toll-like Receptor (TLR) Keap1-Nrf2 Heme Oxygenase (HO) Dihydroorotate Dehydrogenase Ferroptosis PAI-1 NF-κB Proton Pump Glutathione Peroxidase Thrombin Insecticide Bacterial	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Pellitorine (Standard) is the analytical standard of Pellitorine (HY-N3097). Pellitorine is a bioactive natural amide compound. Pellitorine can competitively antagonize the activation of TRPV1 by Capsaicin (HY-10448), thereby reducing pain signal transmission. Pellitorine improves cognitive dysfunction by upregulating the BDNF-ERK1/2-CREB and Nrf2-HO-1 pathways. Pellitorine exerts anti-inflammatory and anti-sepsis effects by inhibiting the release of high mobility group protein B1 (HMGB1) and the expression of RAGE/TLR4. Pellitorine exerts its antithrombotic effect by prolonging the clotting time, inhibiting the activity of clotting factors and thrombin. Pellitorine inhibits lipid peroxidation and resists ferroptosis by upregulating GPX4 and DHODH. Pellitorine kills Aedes aegypti mosquito larvae by inhibiting V-type H⁺-ATPase and aquaporin 4 (AaAQP4). Pellitorine exhibits anti-cancer activity (e.g., leukemia and breast cancer) and has inhibitory effects on certain bacteria.

HY-19517

R1663	Endogenous Metabolite	Cardiovascular Disease
R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .

HY-165360

JJ1	Thrombin	Cardiovascular Disease
JJ1 is a selective *α-thrombin* inhibitor with a K_i of 0.019 μM. JJ1 directly binds to the active site of α-thrombin to block its catalytic activity. JJ1 exhibits antithrombotic effects and prolongs activated partial thromboplastin time, prothrombin time, and tail bleeding time in mice. JJ1 can be used for the research of thrombotic diseases .

HY-N3919

γ-Methoxyisoeugenol	Others	Cardiovascular Disease
γ-Methoxyisoeugenol (Compound 5) is an anticoagulant agent that remarkably prolongs the thrombin time with a good dose-effect relationship at concentrations from 6.25 to 100 mM, but shows no significant differences in prothrombin time .

HY-116363A

(21S)-Argatroban	Drug Isomer Thrombin	Cardiovascular Disease
(21S)-Argatroban is an isomer of Argatroban (HY-B0375) and is a *thrombin* inhibitor. (21S)-Argatroban can prolong blood clotting time, reduces platelet adhesion and aggregation .

HY-N17623

Ainsliaeasin C	Thrombin	Cardiovascular Disease
Ainsliaeasin C, a 7-hydroxycoumarin derivative, is an orally active anticoagulant agent that can be found in Ainsliaea fragrans. Ainsliaeasin C exerts anticoagulant activity both in vitro and in vivo. Ainsliaeasin C can be used for the research on thrombotic disorders .

HY-165180

Lyso-sulfatide (bovine) sodium Psychosine 3′-O-sulfate sodium; Psychosine 3′-sulfate sodium	Biochemical Assay Reagents Factor Xa	Metabolic Disease
Lyso-sulfatide (bovine) sodium is a phospholipid component derived from sphingolipid catabolism and a potent factor Xa inhibitor and anticoagulant. Lyso-sulfatide (bovine) sodium binds directly to factor Xa and inhibits prothrombin activation mediated by the prothrombinase complex, thereby prolonging factor Xa-induced plasma clotting time and suppressing thrombin generation. Lyso-sulfatide (bovine) sodium serves as a reliable lipid membrane mimic for studying cell membrane structure, function, and molecular interactions .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library	1,437 compounds
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,437 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Coagulation and Anti-coagulation Compound Library

1,437 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,437 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Cat. No.	Product Name	Target	Research Area